Summary
Amgen Inc. (AMGN) has filed an 8-K report detailing a significant debt offering completed on February 15, 2023. The company entered into an underwriting agreement to issue and sell a substantial aggregate principal amount of senior notes across various maturity dates, totaling approximately $23.4 billion. These new notes will rank equally with Amgen's other senior unsecured debt and will mature between 2025 and 2063, with coupon rates ranging from 5.150% to 5.750%. The proceeds from this offering are not explicitly stated in this filing but are typically used for general corporate purposes, potential acquisitions, or refinancing existing debt. Investors should note the closing date for this offering is expected to be March 2, 2023.
Key Highlights
- 1Amgen Inc. entered into a material definitive agreement for a significant debt offering.
- 2The company will issue and sell approximately $23.4 billion in aggregate principal amount of senior notes.
- 3The notes have varying maturity dates, ranging from 2025 to 2063.
- 4Interest rates for the senior notes range from 5.150% to 5.750%.
- 5The notes are senior unsecured debt and rank equally with other existing senior unsecured indebtedness.
- 6The offering is expected to close on March 2, 2023, subject to customary conditions.
- 7Key underwriters include Citigroup Global Markets Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC, and Mizuho Securities USA LLC.